SEC
CBAY

Seven Eight Capital’s Cymabay Therapeutics CBAY Stock Holding History

Seven Eight Capital’s Portfolio CBAY Stock Details CBAY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		– Sell
-41,556
Closed -$620K – 886
2023
Q3 		$620K Buy
+41,556
New +$551K 0.07% 346

Other funds holding CBAY

ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Seven Eight Capital's CBAY Position: Q4 2023 in Review

Seven Eight Capital sold out of Cymabay Therapeutics (CBAY) in Q4 2023, closing a stake of 41,556 shares — an estimated $620K sold.

Seven Eight Capital first reported a position in CBAY in Q3 2023 and held it in 1 quarter. The position peaked at $620K in Q3 2023. 200 funds tracked by Wall St. Rank hold CBAY as of Q4 2023.

  • Seven Eight Capital reported no remaining Cymabay Therapeutics position as of Q4 2023 after selling out during the quarter.
  • Seven Eight Capital sold 41,556 Cymabay Therapeutics shares in Q4 2023, an estimated $620K.
  • Seven Eight Capital first reported a position in Cymabay Therapeutics in Q3 2023 and held it in 1 quarter.
  • Seven Eight Capital's Cymabay Therapeutics position peaked at $620K in Q3 2023.
  • 200 funds tracked by Wall St. Rank held Cymabay Therapeutics as of Q4 2023.

Based on Seven Eight Capital's 13F filing for Q4 2023, filed 13 Feb 2024.